[Clinical use of combined radiation and hyperthermia therapy at the National Cancer Center Hospital].
At the National Cancer Center Hospital, Tokyo, hyperthermia combined with radiation was started in February 1982. At first BSD-1000 was introduced into clinical practice, followed by Thermotron RF-8 which utilizes radio frequency and then Aloka HMS-020 which utilizes microwaves. This study involved a total of 116 evaluable patients (128 lesions) from a series of patients treated by hyperthermia during a 4-year period up to March 1986. The sites of the tumors were the lower extremities in 7 patients, upper abdomen in 18, pelvic cavity in 18 patients and superficial in 82. Among 82 superficial lesions 34 were classified as showing CR and another 23 as showing PR, with a response rate of 69.5%. In 7 patients with tumors of the lower extremities none was classified as having CR or PR, the response rate being 0%. Eighteen upper abdominal tumors showed a response rate of 16.7%, with 1 of them being categorized as showing CR and 2 as showing PR. Eighteen pelvic tumors showed a response rate of 27.8%, with 1 of them being categorized as showing CR and 4 as showing PR. In 3 patients with tumors of thoracic cavity none was classified as having CR or PR, the response rate being 0%.
D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000628:therapy; D002173:Cancer Care Facilities; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D006979:Hyperthermia, Induced / Q000295:instrumentation; D008297:Male; D008545:Melanoma / Q000628:therapy; D009369:Neoplasms / Q000532:radiotherapy / Q000628:therapy*; D011379:Prognosis; D011879:Radiotherapy Dosage; D012186:Retroperitoneal Neoplasms / Q000628:therapy; D012208:Rhabdomyosarcoma / Q000628:therapy; D012983:Soft Tissue Neoplasms / Q000628:therapy